Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions...

연구 요약

Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital.

The International journal of risk & safety in medicine 학술지에 발표된 이 연구는 Reddy MS, Ganachari MS, Kini P 외 연구팀이 수행하였습니다.

이 연구는 'Impact of proton pump inhibitors on clinical outcomes and adverse drug reactions in antiplatelet therapy: A prospective study from an Indian hospital.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BackgroundCoronary artery disease (CAD) management relies on antiplatelet therapy to prevent atherothrombotic events but increases gastrointestinal (GI) bleeding risk. Proton pump inhibitors (PPIs) are recommended for gastroprotection, though their effect on cardiovascular outcomes remains debated.ObjectivesTo evaluate the impact of PPI co-therapy on GI bleeding, cardiovascular events, adverse drug reactions (ADRs), and drug-drug interactions (DDIs) in patients on mono or dual antiplatelet therapy.MethodsA prospective observational study was conducted over 4 months in a tertiary care hospital. Patients on mono (MAPT) or dual antiplatelet therapy (DAPT), with or without PPIs, were included. Data on demographics, clinical outcomes, ADRs, and DDIs were analyzed.ResultsOf 174 patients, 48 received DAPT + PPI, 62 DAPT only, 34 MAPT + PPI, and 30 MAPT only. GI bleeding incidence was lower in PPI groups (DAPT + PPI: 6.25%, MAPT + PPI: 2.9%) versus non-PPI groups (DAPT only: 21%, MAPT only: 13.3%). Cardiovascular outcomes were unaffected (Myocardial Infarction: 27.1% vs 38.7% in DAPT + PPI vs DAPT only). 91 ADRs were reported, mainly GI bleeding (23.1%) and dyspnea (16.5%). Major DDIs included aspirin + clopidogrel (24.8%) and aspirin + ticagrelor (17.3%).ConclusionPPI co-prescription significantly reduced GI bleeding without compromising cardiovascular outcomes, supporting guideline-based prophylaxis in CAD patients receiving antiplatelet therapy.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41755737)